Sphingosine-1-phosphate receptor agonist fingolimod increases myocardial salvage and decreases adverse postinfarction left ventricular remodeling in a porcine model of ischemia/reperfusion

Circulation

Volumn 133, Issue 10, 2016, Pages 954-966

  Santos Gallego, Carlos G ^a   Vahl, Torsten P ^a,b   Goliasch, Georg ^a,c   Picatoste, Belen ^a   Arias, Teresa ^a,e   Ishikawa, Kiyotake ^a   Njerve, Ida U ^a,d   Sanz, Javier ^a   Narula, Jagat ^a   Sengupta, Partho P ^a   Hajjar, Roger J ^a   Fuster, Valentin ^a,e   Badimon, Juan J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

apoptosis; cardiovascular diseases; ischemia; models, animal; myocardial infarction; reperfusion injury; ventricular remodeling

Indexed keywords

FINGOLIMOD; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SODIUM CHLORIDE; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; ENZYME ACTIVATION; FIBROSING ALVEOLITIS; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; NONHUMAN; PORCINE MODEL; PRIORITY JOURNAL; REPERFUSION INJURY; AGONISTS; ANIMAL; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY; PHYSIOLOGY; PIG; PROCEDURES; SALVAGE THERAPY;

ANIMALS; DISEASE MODELS, ANIMAL; FINGOLIMOD HYDROCHLORIDE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; RECEPTORS, LYSOSPHINGOLIPID; SALVAGE THERAPY; SWINE; VENTRICULAR REMODELING;

EID: 84960540823     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.012427     Document Type: Article

References (54)

1. De Luca G, Suryapranata H, Ottervanger JP, Antman EM, Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 2004 109 1223 1225. doi: 10.1161/01.CIR.0000121424.76486.20
2. Yellon DM, Hausenloy DJ, Myocardial reperfusion injury. N Engl J Med 2007 357 1121 1135. doi: 10.1056/NEJMra071667
3. Heusch G, Cardioprotection: chances and challenges of its translation to the clinic. Lancet 2013 381 166 175. doi: 10.1016/S0140-6736(12)60916-7
4. Heusch G, Libby P, Gersh B, Yellon D, Böhm M, Lopaschuk G, Opie L, Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 2014 383 1933 1943. doi: 10.1016/S0140-6736(14)60107-0
5. Spiegel S, Milstien S, Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003 4 397 407. doi: 10.1038/nrm1103
6. Xiang SY, Ouyang K, Yung BS, Miyamoto S, Smrcka AV, Chen J, Heller Brown J, PLCε PKD1, and SSH1L transduce RhoA signaling to protect mitochondria from oxidative stress in the heart. Sci Signal 2013 6 ra108. doi: 10.1126/scisignal.2004405
7. Karliner JS, Sphingosine kinase and sphingosine 1-phosphate in the heart: a decade of progress. Biochim Biophys Acta 2013 1831 203 212. doi: 10.1016/j.bbalip.2012.06.006
8. Man K, Ng KT, Lee TK, Lo CM, Sun CK, Li XL, Zhao Y, Ho JW, Fan ST, FTY720 attenuates hepatic ischemia-reperfusion injury in normal and cirrhotic livers. Am J Transplant 2005 5 40 49. doi: 10.1111/j.1600-6143.2004.00642.x
9. Delbridge MS, Shrestha BM, Raftery AT, El Nahas AM, Haylor JL, Reduction of ischemia-reperfusion injury in the rat kidney by FTY720, a synthetic derivative of sphingosine. Transplantation 2007 84 187 195. doi: 10.1097/01.tp.0000269794.74990.da
10. Wei Y, Yemisci M, Kim HH, Yung LM, Shin HK, Hwang SK, Guo S, Qin T, Alsharif N, Brinkmann V, Liao JK, Lo EH, Waeber C, Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol 2011 69 119 129. doi: 10.1002/ana.22186
11. Wacker BK, Park TS, Gidday JM, Hypoxic preconditioning-induced cerebral ischemic tolerance: role of microvascular sphingosine kinase 2. Stroke 2009 40 3342 3348. doi: 10.1161/STROKEAHA.109.560714
12. Karliner JS, Honbo N, Summers K, Gray MO, Goetzl EJ, The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2001 33 1713 1717. doi: 10.1006/jmcc.2001.1429
13. Tao R, Zhang J, Vessey DA, Honbo N, Karliner JS, Deletion of the sphingosine kinase-1 gene influences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes. Cardiovasc Res 2007 74 56 63. doi: 10.1016/j.cardiores.2007.01.015
14. Jin ZQ, Zhou HZ, Zhu P, Honbo N, Mochly-Rosen D, Messing RO, Goetzl EJ, Karliner JS, Gray MO, Cardioprotection mediated by sphingosine-1-phosphate and ganglioside GM-1 in wild-type and PKC epsilon knockout mouse hearts. Am J Physiol Heart Circ Physiol 2002 282 H1970 H1977. doi: 10.1152/ajpheart.01029.2001
15. Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN, Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol 2002 34 509 518. doi: 10.1006/jmcc.2002.1533
16. Duan HF, Wang H, Yi J, Liu HJ, Zhang QW, Li LB, Zhang T, Lu Y, Wu CT, Wang LS, Adenoviral gene transfer of sphingosine kinase 1 protects heart against ischemia/reperfusion-induced injury and attenuates its postischemic failure. Hum Gene Ther 2007 18 1119 1128. doi: 10.1089/hum.2007.036
17. Means CK, Xiao CY, Li Z, Zhang T, Omens JH, Ishii I, Chun J, Brown JH, Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2007 292 H2944 H2951. doi: 10.1152/ajpheart.01331.2006
18. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, Aradhye S, Burtin P, Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010 9 883 897. doi: 10.1038/nrd3248
19. Kappos L, Radue EW, O?Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010 362 387 401. doi: 10.1056/NEJMoa0909494
20. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010 362 402 415. doi: 10.1056/NEJMoa0907839
21. Zhang J, Honbo N, Goetzl EJ, Chatterjee K, Karliner JS, Gray MO, Signals from type 1 sphingosine 1-phosphate receptors enhance adult mouse cardiac myocyte survival during hypoxia. Am J Physiol Heart Circ Physiol 2007 293 H3150 H3158. doi: 10.1152/ajpheart.00587.2006
22. Hofmann U, Burkard N, Vogt C, Thoma A, Frantz S, Ertl G, Ritter O, Bonz A, Protective effects of sphingosine-1-phosphate receptor agonist treatment after myocardial ischaemia-reperfusion. Cardiovasc Res 2009 83 285 293. doi: 10.1093/cvr/cvp137
23. Egom EE, Ke Y, Musa H, Mohamed TM, Wang T, Cartwright E, Solaro RJ, Lei M, FTY720 prevents ischemia/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling. J Mol Cell Cardiol 2010 48 406 414. doi: 10.1016/j.yjmcc.2009.10.009
24. Vessey DA, Li L, Imhof I, Honbo N, Karliner JS, FTY720 postconditions isolated perfused heart by a mechanism independent of sphingosine kinase 2 and different from S1P or ischemic postconditioning. Med Sci Monit Basic Res 2013 19 126 132. doi: 10.12659/MSMBR.883877
25. Heusch G, Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res 2015 116 674 699. doi: 10.1161/CIRCRESAHA.116.305348
26. Jin ZQ, Zhang J, Huang Y, Hoover HE, Vessey DA, Karliner JS, A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury. Cardiovasc Res 2007 76 41 50. doi: 10.1016/j.cardiores.2007.05.029
27. Gomez L, Paillard M, Price M, Chen Q, Teixeira G, Spiegel S, Lesnefsky EJ, A novel role for mitochondrial sphingosine-1-phosphate produced by sphingosine kinase-2 in PTP-mediated cell survival during cardioprotection. Basic Res Cardiol 2011 106 1341 1353. doi: 10.1007/s00395-011-0223-7
28. Theilmeier G, Schmidt C, Herrmann J, Keul P, Schäfers M, Herrgott I, Mersmann J, Larmann J, Hermann S, Stypmann J, Schober O, Hildebrand R, Schulz R, Heusch G, Haude M, von Wnuck Lipinski K, Herzog C, Schmitz M, Erbel R, Chun J, Levkau B, High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 2006 114 1403 1409. doi: 10.1161/CIRCULATIONAHA.105.607135
29. Jin ZQ, Goetzl EJ, Karliner JS, Sphingosine kinase activation mediates ischemic preconditioning in murine heart. Circulation 2004 110 1980 1989. doi: 10.1161/01.CIR.0000143632.06471.93
30. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, André-Fouët X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M, Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008 359 473 481. doi: 10.1056/NEJMoa071142
31. Skyschally A, Schulz R, Heusch G, Cyclosporine A at reperfusion reduces infarct size in pigs. Cardiovasc Drugs Ther 2010 24 85 87. doi: 10.1007/s10557-010-6219-y
32. Heusch G, Musiolik J, Gedik N, Skyschally A, Mitochondrial STAT3 activation and cardioprotection by ischemic postconditioning in pigs with regional myocardial ischemia/reperfusion. Circ Res 2011 109 1302 1308. doi: 10.1161/CIRCRESAHA.111.255604
33. Kelly RF, Lamont KT, Somers S, Hacking D, Lacerda L, Thomas P, Opie LH, Lecour S, Ethanolamine is a novel STAT-3 dependent cardioprotective agent. Basic Res Cardiol 2010 105 763 770. doi: 10.1007/s00395-010-0125-0
34. Yang Z, Day YJ, Toufektsian MC, Xu Y, Ramos SI, Marshall MA, French BA, Linden J, Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes. Circulation 2006 114 2056 2064. doi: 10.1161/CIRCULATIONAHA.106.649244
35. Wang G, Kim RY, Imhof I, Honbo N, Luk FS, Li K, Kumar N, Zhu BQ, Eberlé D, Ching D, Karliner JS, Raffai RL, The immunosuppressant FTY720 prolongs survival in a mouse model of diet-induced coronary atherosclerosis and myocardial infarction. J Cardiovasc Pharmacol 2014 63 132 143. doi: 10.1097/FJC.0000000000000031
36. Kelle S, Roes SD, Klein C, Kokocinski T, de Roos A, Fleck E, Bax JJ, Nagel E, Prognostic value of myocardial infarct size and contractile reserve using magnetic resonance imaging. J Am Coll Cardiol 2009 54 1770 1777. doi: 10.1016/j.jacc.2009.07.027
37. Wu E, Ortiz JT, Tejedor P, Lee DC, Bucciarelli-Ducci C, Kansal P, Carr JC, Holly TA, Lloyd-Jones D, Klocke FJ, Bonow RO, Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart 2008 94 730 736. doi: 10.1136/hrt.2007.122622
38. Hofmann U, Hu K, Walter F, Burkard N, Ertl G, Bauersachs J, Ritter O, Frantz S, Bonz A, Pharmacological pre-and post-conditioning with the sphingosine-1-phosphate receptor modulator FTY720 after myocardial ischaemia-reperfusion. Br J Pharmacol 2010 160 1243 1251. doi: 10.1111/j.1476-5381.2010.00767.x
39. Eitel I, Desch S, Fuernau G, Hildebrand L, Gutberlet M, Schuler G, Thiele H, Prognostic significance and determinants of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. J Am Coll Cardiol 2010 55 2470 2479. doi: 10.1016/j.jacc.2010.01.049
40. Masci PG, Ganame J, Strata E, Desmet W, Aquaro GD, Dymarkowski S, Valenti V, Janssens S, Lombardi M, Van de Werf F, L?Abbate A, Bogaert J, Myocardial salvage by CMR correlates with LV remodeling and early ST-segment resolution in acute myocardial infarction. JACC Cardiovasc Imaging 2010 3 45 51. doi: 10.1016/j.jcmg.2009.06.016
41. Williams MJ, Odabashian J, Lauer MS, Thomas JD, Marwick TH, Prognostic value of dobutamine echocardiography in patients with left ventricular dysfunction. J Am Coll Cardiol 1996 27 132 139. doi: 10.1016/0735-1097(95)00393-2
42. Stanton T, Leano R, Marwick TH, Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring. Circ Cardiovasc Imaging 2009 2 356 364. doi: 10.1161/CIRCIMAGING.109.862334
43. Hung CL, Verma A, Uno H, Shin SH, Bourgoun M, Hassanein AH, McMurray JJ, Velazquez EJ, Kober L, Pfeffer MA, Solomon SD, VALIANT Investigators Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction. J Am Coll Cardiol 2010 56 1812 1822. doi: 10.1016/j.jacc.2010.06.044
44. Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE, Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging 2011 4 98 108. doi: 10.1016/j.jcmg.2010.10.008
45. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ, Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987 76 44 51
46. Migrino RQ, Young JB, Ellis SG, White HD, Lundergan CF, Miller DP, Granger CB, Ross AM, Califf RM, Topol EJ, End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality: the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators. Circulation 1997 96 116 121
47. Verma A, Meris A, Skali H, Ghali JK, Arnold JM, Bourgoun M, Velazquez EJ, McMurray JJ, Kober L, Pfeffer MA, Califf RM, Solomon SD, Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovasc Imaging 2008 1 582 591. doi: 10.1016/j.jcmg.2008.05.012
48. Cohn JN, Ferrari R, Sharpe N, International Forum on Cardiac Remodeling Cardiac remodeling: concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000 35 569 582
49. van Berlo JH, Maillet M, Molkentin JD, Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest 2013 123 37 45. doi: 10.1172/JCI62839
50. Haq S, Choukroun G, Lim H, Tymitz KM, del Monte F, Gwathmey J, Grazette L, Michael A, Hajjar R, Force T, Molkentin JD, Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 2001 103 670 677
51. Benedict CR, Shelton B, Johnstone DE, Francis G, Greenberg B, Konstam M, Probstfield JL, Yusuf S, Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction: SOLVD Investigators. Circulation 1996 94 690 697
52. Güder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G, Angermann CE, Störk S, Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 2007 115 1754 1761. doi: 10.1161/CIRCULATIONAHA.106.653964
53. Raake PW, Schlegel P, Ksienzyk J, Reinkober J, Barthelmes J, Schinkel S, Pleger S, Mier W, Haberkorn U, Koch WJ, Katus HA, Most P, Müller OJ, AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J 2013 34 1437 1447. doi: 10.1093/eurheartj/ehr447
54. Heusch G, Skyschally A, Schulz R, The in-situ pig heart with regional ischemia/reperfusion: ready for translation. J Mol Cell Cardiol 2011 50 951 963. doi: 10.1016/j.yjmcc.2011.02.016